Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01476696 · ClinicalTrials.gov registry record · Phase 2
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT01476696 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 33 participants.
The verdict
NCT01476696, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the correct prasugrel dosage to be given to children with sickle cell disease (SCD).
Interventions
- DRUG Prasugrel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2011-11 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01476696
The ClinicalTrials.gov registry entry for NCT01476696 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Prasugrel is the first listed.
NCT01476696 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01476696 about?
NCT01476696 is a clinical study titled "A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease". The purpose of this study is to determine the correct prasugrel dosage to be given to children with sickle cell disease (SCD).
What is the current status of trial NCT01476696?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2011-11. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01476696?
The interventions under investigation include: Prasugrel (DRUG).
Who is sponsoring clinical trial NCT01476696?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.